Australia news live: Drugs regulator to crack down on illegal peptides; Labor to spend $100m on arthritis research

The Australian federal government announced on June 11, 2026, a commitment to invest an additional $100 million over the next decade to fund research into arthritis and musculoskeletal conditions. This initiative, part of the government's Medical Research Future Fund, aims to address the significant impact of these conditions on approximately 7 million Australians, affecting their capacity to work, remain active, and engage in daily life. Prime Minister Anthony Albanese and Health Minister Mark Butler are set to formally unveil the new arthritis and musculoskeletal conditions research mission. Concurrently, the Therapeutic Goods Administration (TGA), Australia's drug regulator, is intensifying its crackdown on the illegal importation and sale of unapproved peptide products. The TGA has identified peptides as a priority concern, alongside substances like melatonin, cannabis, and weight loss medications, due to increasing evidence of potential risks to consumers from their unregulated availability. This regulatory action reflects a broader effort to enhance consumer safety and oversight of therapeutic goods in the Australian market.